PMID- 25827800
OWN - NLM
STAT- MEDLINE
DCOM- 20160114
LR  - 20150401
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 30 Suppl 1
DP  - 2015 Mar
TI  - Pretreatment prediction of symptom response to proton pump inhibitor therapy.
PG  - 25-30
LID - 10.1111/jgh.12744 [doi]
AB  - BACKGROUND AND AIM: This prospective pilot study investigated whether it is 
      possible to predict the therapeutic response in both the early phase (1 week) and 
      sustained phase (4 weeks) before starting proton pump inhibitor (PPI) therapy for 
      functional dyspepsia (FD) or non-erosive reflux disease (NERD). METHODS: We 
      administered rabeprazole 10 mg for 4 weeks to NERD/FD patients, who also answered 
      a modified version of the Frequency Scale for Symptoms of gastroesophageal reflux 
      disease (GERD) (FSSG), which added a pain score to the FSSG. Total score (TS), 
      reflux score (RS), dysmotility score (DS), and pain score (PS) were analyzed. 
      Symptom improvement was defined as >/= 50% improvement in each score. RESULTS: We 
      enrolled 83 patients (age [mean +/- SD] 50.8 +/- 15.8 years, 29 males, 54 females), 
      of whom 62 could be classified into four groups: achieved symptom improvement 
      within 1 week and maintained it for 4 weeks (Early-R, 40.3%); achieved symptom 
      improvement within 1 week but lost it after 4 weeks (Temp-R, 9.7%); did not 
      achieve symptom improvement within 1 week but did after 4 weeks (Late-R, 9.7%); 
      and no improvement (Non-R, 40.3%). Mean TS, RS, DS, and PS in the Non-R group 
      were significantly higher than in the Early-R group (23.9, 10.5, 11.0, and 2.4 vs 
      14.3, 6.8, 6.4, and 1.2). However, the Temp-R, Late-R, and Non-R groups could not 
      be distinguished by TS, RS, or DS. CONCLUSION: The magnitude of the pretreatment 
      modified FSSG score seemed to be associated with the response at 1 week and 4 
      weeks.
CI  - (c) 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Nagahara, Akihito
AU  - Nagahara A
AD  - Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, 
      Japan.
FAU - Miwa, Hiroto
AU  - Miwa H
FAU - Asaoka, Daisuke
AU  - Asaoka D
FAU - Shimada, Yuji
AU  - Shimada Y
FAU - Sasaki, Hitoshi
AU  - Sasaki H
FAU - Matsumoto, Kenshi
AU  - Matsumoto K
FAU - Osada, Taro
AU  - Osada T
FAU - Hojo, Mariko
AU  - Hojo M
FAU - Watanabe, Sumio
AU  - Watanabe S
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Dyspepsia/diagnosis/*drug therapy
MH  - Female
MH  - Forecasting
MH  - Gastroesophageal Reflux/diagnosis/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Rabeprazole/*administration & dosage
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - functional dyspepsia
OT  - non-erosive reflux disease
OT  - prediction
OT  - proton pump inhibitor
EDAT- 2015/04/02 06:00
MHDA- 2016/01/15 06:00
CRDT- 2015/04/02 06:00
PHST- 2015/04/02 06:00 [entrez]
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2016/01/15 06:00 [medline]
AID - 10.1111/jgh.12744 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:25-30. doi: 10.1111/jgh.12744.